SCHEMBL1747191

SCHEMBL1747191

CCOC(=O)CCc1ccc(NC(=O)c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.60
PGR P06401 2/20 0.59
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
HPGD P15428 1/20 0.57
CRHBP P24387 1/20 0.57
CRHR2 Q13324 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 3/20 0.53
MAPK1 P28482 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
LMNA P02545 2/20 0.53
NR1H4 Q96RI1 1/20 0.53
POLB P06746 2/20 0.52
SRD5A2 P31213 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773677 0.86 FFAR1 (0.66) NPC1RAB9AHPGDCRHBPCRHR2
SCHEMBL1747121 0.85 HDAC1 (0.79) HDAC1PGRNPC1RAB9ATRPV1
SCHEMBL3131697 0.84 KDM4E (0.53) HDAC1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL17084712 0.82 PGR (0.72) HDAC1PGRNPC1RAB9AHPGD
SCHEMBL155094 0.82 PGR (0.72) HDAC1PGRNPC1RAB9AHPGD
SCHEMBL5488236 0.82 HDAC1 (1.00) HDAC1PGRNPC1RAB9ASMN1; SMN2
SCHEMBL15948094 0.81 RAB9A (0.59) NPC1RAB9AHPGDCRHBPCRHR2
SCHEMBL22192258 0.79 PGR (0.93) HDAC1PGRNPC1RAB9AHPGD
SCHEMBL28663154 0.79 MAPK14 (0.65) NPC1RAB9AHPGDSMN1; SMN2LMNA
SCHEMBL11527718 0.79 CYP4F2 (0.60) L3MBTL1RAB9AHPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR HDAC1 2106/4885L3MBTL1 4392/4885PGR 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.